Verisante Technology Inc (VRSEF) 0.1500 $VRSEF
Verisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board
Marketwire - Tue Jul 29, 9:02AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, is pleased to welcome Dr. Kenneth Beer, MD, PA and Dr. Wm. Philip Werschler, MD, FAAD, FAACS, onto the Company's Clinical Advisory Board.
Verisante Technology, Inc. Announces Non Brokered Private Placement and Letter of Intent for the Exclusive Sales and Marketing Rights for Cancer Detection Technology in China
Marketwire - Wed Jun 25, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today it has closed a non-brokered private placement of 2,000,000 common shares at a price of $0.15 per share for gross proceeds of $300,000.
Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura(TM) for Skin Cancer Detection
Marketwire - Tue Jun 10, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today that the Company is partnering with the BC Cancer Foundation to showcase Verisante Aura(TM), a device for the detection of skin cancer.
Edison Research Initiates Coverage on Verisante Technology, Inc.
Marketwire - Thu Jun 05, 1:54AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today that Edison Research, an investment research firm, has initiated coverage on the Company.
Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Update
Marketwire - Thu Jun 05, 1:38AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014.
Verisante Technology Inc. Announces Preliminary License Agreement with Astoria Capital for Cancer Detection Technology
Marketwire - Thu May 29, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today it has signed a letter of intent, subject to a final definitive agreement, with Astoria Capital SA (WAR: ACL) to sub-license and, in turn, finance the development and commercialization of Verisante's cancer detection technology for the upper gastrointestinal system ("Upper GI Instrument" .
Verisante Technology's Early Cancer Detection Devices, CEO Clip Video
Newsfile Corp - Thu Mar 20, 10:01AM CDT
full story)
Verisante Completes Private Placement
Marketwire - Tue Mar 18, 12:04PM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS) (OTCQX: VRSEF) (the "Company" or "Verisante" , announced today that it has closed a non-brokered private placement of 2,827,000 units ("Units" at a price of $0.17 per Unit for gross proceeds of $480,590. Each Unit consists of one common share of the Company and one common share purchase warrant (a "Warrant" . Each Warrant entitles the holder to acquire a common share at a price of $0.25 for a period of 24 months from the date of issuance, subject to certain acceleration provisions contained within the warrant certificate.
Verisante Technology, Inc. Expands Intellectual Property Portfolio
Marketwire - Wed Mar 12, 9:01AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today that the Chinese Patent Office has issued a decision to grant Patent Application No. 2006800074 entitled "Methods and Apparatus for Measuring Cancerous Changes from Reflectance Spectral Measurements Obtained During Endoscopy Imaging".
Verisante Technology, Inc. Grows Sales and Marketing Team
Marketwire - Wed Feb 26, 9:02AM CST
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante" , a leader in cancer detection technology, announced today that the Company has hired Jason Mangler as Director of Sales to guide the Company's world-wide sales and marketing strategy. Verisante has also hired Kim Ellis, as the Company's Sales Representative for Western Canada.
Launch: Ericsson brings capacity with 'Small Cell as a Service'
M2 - Thu Feb 13, 7:16AM CST
- Enables increased network capacity in environments where large numbers of people gather and consume large amounts of data
Verisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board
Marketwire - Tue Jul 29, 9:02AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, is pleased to welcome Dr. Kenneth Beer, MD, PA and Dr. Wm. Philip Werschler, MD, FAAD, FAACS, onto the Company's Clinical Advisory Board. Verisante Technology, Inc. Announces Non Brokered Private Placement and Letter of Intent for the Exclusive Sales and Marketing Rights for Cancer Detection Technology in China
Marketwire - Wed Jun 25, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today it has closed a non-brokered private placement of 2,000,000 common shares at a price of $0.15 per share for gross proceeds of $300,000. Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura(TM) for Skin Cancer Detection
Marketwire - Tue Jun 10, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today that the Company is partnering with the BC Cancer Foundation to showcase Verisante Aura(TM), a device for the detection of skin cancer. Edison Research Initiates Coverage on Verisante Technology, Inc.
Marketwire - Thu Jun 05, 1:54AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today that Edison Research, an investment research firm, has initiated coverage on the Company. Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Update
Marketwire - Thu Jun 05, 1:38AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014. Verisante Technology Inc. Announces Preliminary License Agreement with Astoria Capital for Cancer Detection Technology
Marketwire - Thu May 29, 8:31AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today it has signed a letter of intent, subject to a final definitive agreement, with Astoria Capital SA (WAR: ACL) to sub-license and, in turn, finance the development and commercialization of Verisante's cancer detection technology for the upper gastrointestinal system ("Upper GI Instrument" . Verisante Technology's Early Cancer Detection Devices, CEO Clip Video
Newsfile Corp - Thu Mar 20, 10:01AM CDT
full story)
Verisante Completes Private Placement
Marketwire - Tue Mar 18, 12:04PM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS) (OTCQX: VRSEF) (the "Company" or "Verisante"
, announced today that it has closed a non-brokered private placement of 2,827,000 units ("Units" at a price of $0.17 per Unit for gross proceeds of $480,590. Each Unit consists of one common share of the Company and one common share purchase warrant (a "Warrant" . Each Warrant entitles the holder to acquire a common share at a price of $0.25 for a period of 24 months from the date of issuance, subject to certain acceleration provisions contained within the warrant certificate. Verisante Technology, Inc. Expands Intellectual Property Portfolio
Marketwire - Wed Mar 12, 9:01AM CDT
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today that the Chinese Patent Office has issued a decision to grant Patent Application No. 2006800074 entitled "Methods and Apparatus for Measuring Cancerous Changes from Reflectance Spectral Measurements Obtained During Endoscopy Imaging". Verisante Technology, Inc. Grows Sales and Marketing Team
Marketwire - Wed Feb 26, 9:02AM CST
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"
, a leader in cancer detection technology, announced today that the Company has hired Jason Mangler as Director of Sales to guide the Company's world-wide sales and marketing strategy. Verisante has also hired Kim Ellis, as the Company's Sales Representative for Western Canada. Launch: Ericsson brings capacity with 'Small Cell as a Service'
M2 - Thu Feb 13, 7:16AM CST
- Enables increased network capacity in environments where large numbers of people gather and consume large amounts of data
